clinical trial · NCT04270760
Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
Amgen·phase2·completed·n = 281
Cardiovascular DiseaseOlpasiranPlacebo
brief summary
Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp\[a\]).
started
Jul 28, 2020
primary completion
Dec 27, 2021
completion
Nov 8, 2022
last updated
Mar 31, 2026
official title
A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) in Subjects With Elevated Lipoprotein(a)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol